Madrigal Pharmaceuticals, Inc. (LON:0JXI)

London flag London · Delayed Price · Currency is GBP · Price in USD
301.62
-5.26 (-1.71%)
At close: Aug 1, 2025
-1.71%
Market Cap5.07B
Revenue (ttm)245.65M
Net Income (ttm)-303.09M
Shares Outn/a
EPS (ttm)-13.91
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume105
Average Volume61
Open305.42
Previous Close306.88
Day's Range301.62 - 307.33
52-Week Range201.25 - 375.14
Beta-0.76
RSI47.55
Earnings DateAug 5, 2025

About United States Steel

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania. [Read more]

Industry Pharmaceutical Preparations
CEO William Sibold
Employees 528
Stock Exchange London Stock Exchange
Ticker Symbol 0JXI
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.